eISSN: 2720-5371
ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
3/2022
vol. 31
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

ANTI-NMDA-R encephalitis: case report

Bünyamin Tosunoğlu
1
,
Hafize Nalan Güneş
1
,
Hatice Mediha Kına
1
,
Burcu Gökçe Çokal
1

  1. Department of Neurology, Ankara Training and Research Hospital, Turkey
Adv Psychiatry Neurol 2022; 31 (3): 138-140
Data publikacji online: 2022/10/22
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Purpose
Anti-N-methyl-D-aspartate receptor encephalitis (NMDA-R) is the most common among autoimmune encephalitis caused by antibodies developed against surface antigens. It was first identified in 2007 as presenting with seizures, autonomic dysfunction and movement disorders, in addition to acute or subacute onset of neuropsychiatric symptoms. Multifocal, nonspecific white matter lesions can be seen on cranial magnetic resonance imaging (MRI). Since paraneoplasia is usually found in the etiology, malignancy should be screened in patients with NMDA-R encephalitis.

Case description
In our case, a 48-year-old patient is presented who has been diagnosed with anti-NMDA-R encephalitis during the examinations, complaining of numbness on the left side of his face, seizures, imbalance, excessive talkativeness and insomnia.

Comment
Autoimmune encephalitis should be considered in patients with suspected autoimmune encephalitis, which takes severe clinical course and fails to respond to treatment adequately; NMDA receptor antibodies and other autoantibody tests should be requested, malignancy screening should be performed and treatment should be started in the early period.

słowa kluczowe:

seizure, encephalitis, paraneoplasia

© 2024 Termedia Sp. z o.o.
Developed by Bentus.